Prevalence, Risk Factors, and Outcomes of Platelet Transfusion Refractoriness in Critically Ill Patients: A Retrospective Cohort Study
Table 4
Characteristics of platelet transfusions by the time to the next transfusion.
Total (N = 1118)
Less than 2 days (N = 643)
2 days or more (N = 475)
value
Platelet count prior to transfusion (x106/L)
Median (Q1, Q3)
31000.0 (16000.0, 50000.0)
28000.0 (14000.0, 45000.0)
37000.0 (19000.0, 58000.0)
<0.001
Number of platelet concentrates per transfusion episode∗
Median (Q1, Q3)
1.0 (1.0, 2.0)
1.0 (1.0, 2.0)
1.0 (1.0, 1.0)
0.04
Platelet increment (x106/L)
Median (Q1, Q3)
6000.0 (−5000.0, 24000.0)
5000.0 (−6000.0, 19000.0)
9000.0 (−4000.0, 29000.0)
<0.001
Platelet product type
N (%∗∗)
Apheresis
111
71 (64.0)
40 (36.0)
0.16
Apheresis-irradiated
163
101 (62.0)
62 (38.0)
0.23
Pooled
608
310 (51.0)
298 (49.0)
<0.001
Pooled-irradiated
157
109 (69.4)
48 (30.6)
0.001
Mixed∗∗∗
79
52 (65.8)
27 (34.2)
0.13
Time to the next platelet transfusion (days)
Median (Q1, Q3)
1.0 (1.0, 2.0)
1.0 (1.0, 1.0)
3.0 (2.0, 4.0)
<0.001
∗Six units of single donor platelets prepared from whole blood were pooled to produce a single pooled platelet concentrate. ∗∗The denominator is the total number of transfusion episodes of the platelet product type. ∗∗∗Mixed indicates aggregate transfusions that were derived from transfusions with 2 or more different platelet products. Q1: first quartile, Q3: third quartile.
